Peripheral blood leukocyte populations and urinary neopterin during chemotherapy in patients with breast cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62690094%3A18450%2F16%3A50005416" target="_blank" >RIV/62690094:18450/16:50005416 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/16:10329615 RIV/00179906:_____/16:10329615 RIV/61989592:15110/16:33160474

Výsledek na webu

<a href="https://www.degruyter.com/view/j/pteridines.ahead-of-print/pterid-2016-0005/pterid-2016-0005.xml" target="_blank" >https://www.degruyter.com/view/j/pteridines.ahead-of-print/pterid-2016-0005/pterid-2016-0005.xml</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/pterid-2016-0005" target="_blank" >10.1515/pterid-2016-0005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Peripheral blood leukocyte populations and urinary neopterin during chemotherapy in patients with breast cancer

Popis výsledku v původním jazyce

Breast cancer is the most common malignant tumor in women in the Western world. Despite the advances in early diagnosis and multidisciplinary treatment, breast cancer remains on of the leading causes of cancer deaths in women. It is now widely accepted that even in patients with apparently localized tumors breast cancer represents a systemic disease. In fact, improved prognosis of patients with breast cancer during the last decades has been caused not only by timely diagnosis, but also by improved systemic therapy. Systemic therapy, including the administration of cytotoxic, hormonal or targeted drugs currently represents an essential integral part of the multidisciplinary management of cancer patients. In patients with breast cancer systemic therapy is commonly administered after surgery in the adjuvant setting. In patients with locally advanced breast cancer, the primary tumor is considered unsuitable for upfront surgery, and systemic treatment is administered as first therapeutic modality, followed by surgery. Based on the observation that this therapeutic approach converts inoperable tumors to tumors that can be surgically treated, primary systemic treatment is also being increasingly used in patients with operable tumors with the aim to allow less extensive surgery. Primary (neoadjuvant) chemotherapy also represents a model system to directly examine the effect of systemic therapy on the tumor and the host-tumor interactions.

Název v anglickém jazyce

Peripheral blood leukocyte populations and urinary neopterin during chemotherapy in patients with breast cancer

Popis výsledku anglicky

Breast cancer is the most common malignant tumor in women in the Western world. Despite the advances in early diagnosis and multidisciplinary treatment, breast cancer remains on of the leading causes of cancer deaths in women. It is now widely accepted that even in patients with apparently localized tumors breast cancer represents a systemic disease. In fact, improved prognosis of patients with breast cancer during the last decades has been caused not only by timely diagnosis, but also by improved systemic therapy. Systemic therapy, including the administration of cytotoxic, hormonal or targeted drugs currently represents an essential integral part of the multidisciplinary management of cancer patients. In patients with breast cancer systemic therapy is commonly administered after surgery in the adjuvant setting. In patients with locally advanced breast cancer, the primary tumor is considered unsuitable for upfront surgery, and systemic treatment is administered as first therapeutic modality, followed by surgery. Based on the observation that this therapeutic approach converts inoperable tumors to tumors that can be surgically treated, primary systemic treatment is also being increasingly used in patients with operable tumors with the aim to allow less extensive surgery. Primary (neoadjuvant) chemotherapy also represents a model system to directly examine the effect of systemic therapy on the tumor and the host-tumor interactions.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13564" target="_blank" >NT13564: Prediktivní faktory patologické odpovědi na neoadjuvantní chemoterapii u nemocných s karcinomem prsu a HER-2 pozitivním nebo triple negativním fenotypem</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pteridines

ISSN

0933-4807

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

3-4

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

9

Strana od-do

67-75

Kód UT WoS článku

000390413200003

EID výsledku v databázi Scopus

—